09/19/23 8:00 AMNasdaq : SRRK clinical trialScholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE TrialEfficacy and safety data at 36 months, and an analysis of patient-reported outcome measures such as fatigue, mobility, and activities of daily living, will be presented during two poster presentations at the 28 th Annual Congress of the World Muscle Society from October 3– 7 in Charleston, South Carolina, USA.. Title: Effect of apitegromab on PEDI-CAT and...RHEA-AIneutral
09/15/23 4:15 PMNasdaq : SRRK managementScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 8,750 shares of its common stock to one newly hired employee, consisting of inducement stock...RHEA-AIneutral
08/18/23 4:15 PMNasdaq : SRRK managementScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 150,938 shares of its common stock to 8 newly hired employees, consisting of inducement stock...RHEA-AIneutral
08/09/23 4:15 PMNasdaq : SRRK earningsScholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business ProgressScholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the second quarter ended June 30, 2023.. “We continue to advance our apitegromab program, notably with the recent presentation of...RHEA-AIneutral
07/13/23 8:00 AMNasdaq : SRRK managementScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 72,625 shares of its common stock to 6 newly hired employees, consisting of inducement stock...RHEA-AIneutral
06/30/23 11:00 AMNasdaq : SRRK clinical trialNew 36-Month Apitegromab Extension Data Reinforce Long-Term Substantial and Sustained Improvement of Motor Function in Phase 2 TOPAZ Trial Patients with Nonambulatory Spinal Muscular AtrophyScholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes at 36 months of treatment with apitegromab. These data showed that continued treatment...RHEA-AIneutral
06/15/23 8:00 AMNasdaq : SRRK managementScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 216,563 shares of its common stock to 8 newly hired employees, consisting of inducement stock...RHEA-AIneutral
06/01/23 4:05 PMNasdaq : SRRK conferencesScholar Rock to Present at the Jefferies Healthcare ConferenceScholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3:00 p.m. ET. A live webcast of the presentation may be accessed by visiting...RHEA-AIneutral
05/10/23 8:00 AMNasdaq : SRRK managementScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock, a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the Company granted inducement equity awards covering an aggregate of 49,176 shares of its common stock to four newly hired employees, consisting of inducement stock...RHEA-AIneutral
05/09/23 7:30 AMNasdaq : SRRK earningsScholar Rock Reports First Quarter 2023 Financial Results and Highlights Business ProgressScholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2023.. Continued progress towards completion of enrollment for Phase 3 SAPPHIRE clinical...RHEA-AIneutral